NEW YORK, Nov. 1, 2018 /PRNewswire/ — AAVP Biosystems, Inc. a developmental stage gene delivery company initially focused on the pursuit of a new therapy for cancer indications, is now named PhageNova Bio, Inc. PhageNova Bio’s hybrid vector platform relies on combining the targeting capability of bacteriophage and the […]
Click here to view original web page at www.prnewswire.com
